Literature DB >> 1541314

Dose-dependent headache response and dilatation of limb and extracranial arteries after three doses of 5-isosorbide-mononitrate.

H K Iversen1, T H Nielsen, K Garre, P Tfelt-Hansen, J Olesen.   

Abstract

The aim of the present study was to compare the ability of different doses of isosorbide-5-mononitrate (5-ISMN) to cause dilatation of medium sized and small arteries, and to examine the intensity and duration of any headache produced. Ten healthy volunteers each received 3 doses of 5-ISMN and placebo on separate days. The diameters of the radial and superficial temporal arteries were repeatedly measured with high frequency ultrasound and pain was scored using a 10 point verbal scale. A clear dose-relationship was found for plasma concentrations and headache, and for changes in the diameter of the temporal artery, but not for the radial artery. It is concluded that headache after 5-ISMN is caused by arterial dilatation or by mechanisms responsible for the arterial dilatation. Ultrasound monitoring of arterial diameters is an important and sensitive tool in the evaluation of nitrates and other vasodilators.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1541314     DOI: 10.1007/bf00314916

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  The effect of intra-arterial papaverine on the regional cerebral blood flow in patients with stroke or intracranial tumor.

Authors:  J Olesen; O B Paulson
Journal:  Stroke       Date:  1971 Mar-Apr       Impact factor: 7.914

2.  Response of large and small coronary arteries to nitroglycerin, NaNO 2 , and adenosine.

Authors:  R L Schnaar; H V Sparks
Journal:  Am J Physiol       Date:  1972-07

3.  Determination of the luminal diameter of the radial artery in man by high frequency ultrasound: a methodological study.

Authors:  T H Nielsen; H K Iversen; P Tfelt-Hansen
Journal:  Ultrasound Med Biol       Date:  1990       Impact factor: 2.998

4.  Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics.

Authors:  Helle K Iversen; Jes Olesen; Peer Tfelt-Hansen
Journal:  Pain       Date:  1989-07       Impact factor: 6.961

5.  Endothelium modulation of the effects of nitroglycerin on blood vessels from dogs with pacing-induced heart failure.

Authors:  C Forster; J S Main; P W Armstrong
Journal:  Br J Pharmacol       Date:  1990-09       Impact factor: 8.739

6.  First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man.

Authors:  U Abshagen; S Spörl-Radun
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

7.  Dose dependence of tolerance during treatment with mononitrates.

Authors:  M Tauchert; W Jansen; A Osterspey; M Fuchs; V Hombach; H H Hilger
Journal:  Z Kardiol       Date:  1983

8.  Usefulness of twice-daily isosorbide-5-mononitrate in preventing development of tolerance in angina pectoris.

Authors:  U Thadani; R Prasad; S F Hamilton; W Voyles; R Doyle; S Karpow; R Reder; S M Teague
Journal:  Am J Cardiol       Date:  1987-09-01       Impact factor: 2.778

9.  Duration of effects and tolerance of slow-release isosorbide-5-mononitrate for angina pectoris.

Authors:  U Thadani; S F Hamilton; E Olson; J L Anderson; R Prasad; W Voyles; R Doyle; E Kirsten; S M Teague
Journal:  Am J Cardiol       Date:  1987-04-01       Impact factor: 2.778

10.  Effects of isosorbide-5-mononitrate on exercise-induced hemodynamic changes in angina pectoris.

Authors:  M Yokota; A Tsunekawa; T Miyahara; S Kamihara; J Kitamura; S Noda; M Koide; M Tsuzuki; I Sotobata
Journal:  Am J Cardiol       Date:  1986-07-01       Impact factor: 2.778

View more
  12 in total

Review 1.  Nitric oxide-related drug targets in headache.

Authors:  Jes Olesen
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

Review 2.  Sweating and vascular responses in the face: normal regulation and dysfunction in migraine, cluster headache and harlequin syndrome.

Authors:  P D Drummond
Journal:  Clin Auton Res       Date:  1994-10       Impact factor: 4.435

Review 3.  Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina pectoris.

Authors:  N S Gunasekara; S Noble
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

4.  Histamine-1 receptor blockade does not prevent nitroglycerin induced migraine. Support for the NO-hypothesis of migraine.

Authors:  L H Lassen; L L Thomsen; C Kruuse; H K Iversen; J Olesen
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

5.  Effects of systemic inhibitors of acid-sensing ion channels 1 (ASIC1) against acute and chronic mechanical allodynia in a rodent model of migraine.

Authors:  Clément Verkest; Emilie Piquet; Sylvie Diochot; Mélodie Dauvois; Michel Lanteri-Minet; Eric Lingueglia; Anne Baron
Journal:  Br J Pharmacol       Date:  2018-09-22       Impact factor: 8.739

6.  Lack of tolerance of headache and radial artery diameter during a 7 hour intravenous infusion of nitroglycerin.

Authors:  H K Iversen; T H Nielsen; P Tfelt-Hansen; J Olesen
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Nitric oxide-induced headache may arise from extracerebral arteries as judged from tolerance to isosorbide-5-mononitrate.

Authors:  Ingelise Christiansen; Helle K Iversen; Jes Olesen; Peer Tfelt-Hansen
Journal:  J Headache Pain       Date:  2008-06-03       Impact factor: 7.277

8.  Venous plasma levels of endothelin-1 are not altered immediately after nitroglycerin infusion in healthy subjects.

Authors:  L L Thomsen; H K Iversen; C Emmeluth; P Bie
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

9.  Inhibition of nitric oxide biosynthesis and carotid arteriovenous anastomotic shunting in the pig.

Authors:  E M van Gelderen; P R Saxena
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

10.  The effect of nitric oxide donors on haemodynamics and blood flow distribution in the porcine carotid circulation.

Authors:  E M van Gelderen; E L De Bruijne; H J Agteresch; P R Saxena
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.